Recommendations for the implementation of Neoral C2 monitoring in clinical practice

被引：69

作者：

Cole, E

Midtvedt, K

Johnston, A

Pattison, J

O'Grady, C

机构：

[1] Univ Toronto, Toronto Gen Hosp, Toronto, ON M5G 2C4, Canada

[2] Natl Hosp Norway, Med Dept Nephrol, N-0027 Oslo, Norway

[3] Barts & London Queen Marys Sch Med & Dent, London EC1M 6BQ, England

[4] Guys Hosp, Renal Unit, London SE1 9RT, England

来源：

TRANSPLANTATION | 2002年 / 73卷 / 09期

关键词：

D O I：

10.1097/00007890-200205151-00004

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

[No abstract available]

引用

收藏

页码：S19 / S22

页数：4

相关论文

共 14 条

[1] COLE E, 2002, AM SOC TRANSPL C APR
[2] *INT NEOR REN TRAN, 2002, IN PRESS AM J TRANSP
[3] KAHAN BD, 2002, CLIN THER, V24, P1
[4] Keown P, 2001, TRANSPLANTATION, V72, P1024
[5] Single-center study utilizing C2 level as monitoring tool in de novo renal transplant recipients treated with Neoral
Keshavamurthy, M
Al Ahmadi, I
Raza, SM
Baynton, R
Al Meshari, K
Al Shaibani, K
[J]. TRANSPLANTATION PROCEEDINGS, 2001, 33 (7-8) : 3112 - 3114
[6] Benefits of cyclosporine microemulsion (Neoral) C2 monitoring are sustained at 1 year in de novo liver transplant recipients
Lake, JR
[J]. TRANSPLANTATION PROCEEDINGS, 2001, 33 (7-8) : 3092 - 3093
[7] Patient management by Neoral C2 monitoring:: An international Consensus statement
Levy, G
Thervet, E
Lake, J
Uchida, K
[J]. TRANSPLANTATION, 2002, 73 (09) : S12 - S18
[8] Improved clinical outcomes for liver transplant recipients using cyclosporine monitoring based on 2-hr post-dose levels (C2)
Levy, G
Burra, P
Cavallari, A
Duvoux, C
Lake, J
Mayer, AD
Mies, S
Pollard, SG
Varo, E
Villamil, F
Johnston, A
[J]. TRANSPLANTATION, 2002, 73 (06) : 953 - 959
[9] Neoral C2 in liver transplant recipients
Levy, GA
[J]. TRANSPLANTATION PROCEEDINGS, 2001, 33 (7-8) : 3089 - 3091
[10] C2 monitoring strategy for optimising cyclosporin immunosuppression from the neoral®1 formulation
Levy, GA
[J]. BIODRUGS, 2001, 15 (05) : 279 - 290